Estonian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Leht 1 alates 175 tulemused
Treatment-related dysgeusia in head and neck cancer patients.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Head and neck cancer patients treated with radiotherapy and/or chemotherapy agents may develop altered taste acuity. This, together with radiation induced xerostomia and dysphagia, is a major contributory factor to the anorexia and concomitant morbidity often seen in this group of patients. This
[Taste dysfunction (dysgeusia) and radioiodine therapy of thyroid cancer - Be aware of side effects by antidepressants and sedatives].
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
In addition to xerostomia, taste dysfunction (hypo-, dysgeusia) is an independent side effect of radioiodine therapy of thyroid cancer. Hypogeusia results from damage of the small mucous salivary glands in the vicinity of the taste buds. Particularly in those patients, who are treated with drugs
[Taste dysfunction (dysgeusia) and radioiodine therapy of thyroid cancer - be aware of side effects by antidepressants and sedatives. Vorschädigung durch Antidepressiva und Sedativa beachten].
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
In addition to xerostomia, taste dysfunction (hypo-, dysgeusia) is an independent side effect of radioiodine therapy of thyroid cancer. Hypogeusia results from damage of the small mucous salivary glands in the vicinity of the taste buds. Particularly in those patients, who are treated with drugs
Baseline Dysgeusia in Chemotherapy-Naïve Non-Small Cell Lung Cancer Patients: Association with Nutrition and Quality of Life.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Purpose: Dysgeusia can be found in 50% of cancer patients undergoing chemotherapy. Nonetheless, dysgeusia can be present in treatment-naïve patients, and may negatively impact nutrition and quality of life. Methods: Treatment-naïve non-small cell lung cancer (NSCLC) was assessed for
Successful treatment of crizotinib-induced dysgeusia by switching to alectinib in ALK-positive non-small cell lung cancer.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
We describe a case of dysgeusia that developed gradually over one week after initiation of crizotinib administration for treatment of ALK-positive non-small cell lung cancer, necessitating discontinuation of the agent. The symptom was accompanied by progressive loss in appetite and body weight.
Dysgeusia in symptomatic syndrome of inappropriate antidiuretic hormone secretion: think of lung cancer.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
The case of a 60-year-old woman who presented with marked dysgeusia to all food and symptomatic syndrome of inappropriate antidiuretic hormone secretion (SIADH) is described. She eventually turned out to have metastatic small cell lung cancer. The case study explores the interesting constellation of
Acupuncture Therapy in Post-Radiation Head-and-Neck Cancer with Dysgeusia
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Background: Radiation therapy for head-and-neck cancer can cause side-effects, including pain, nausea, vomiting, sensory disorders such as anosmia and dysgeusia, dysphagia, xerostomia, hot flashes, fatigue, sleep disorders, and even anxiety and depression disorders. Therapies using
Photobiomodulation Therapy in the Treatment of Oral Mucositis, Dysgeusia and Oral Dryness as Side-Effects of Head and Neck Radiotherapy in a Cancer Patient: A Case Report.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Successful management of oral mucositis, dysgeusia and oral dryness was made with fivesessions of photobiomodulation. The severity of oral mucositis was measured according to the World Health Organization scale for the assessment of oral mucositis. Dysgeusia testing was performed according to the
A systematic review of dysgeusia induced by cancer therapies.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
OBJECTIVE
The purpose was to review relevant scientific papers written since 1989 which focused on the prevalence and management of dysgeusia as an oral side effect of cancer treatment.
METHODS
Our literature search was limited to English language papers published between 1990 and 2008. A total of
Analysis of Side Effect Profile of Alopecia, Nail Changes, Peripheral Neuropathy, and Dysgeusia in Prostate Cancer Patients Treated With Docetaxel and Cabazitaxel.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND
We hypothesized that the adverse event (AE) profile of cabazitaxel with regard to alopecia, nail changes, neuropathy, and dysgeusia differs from docetaxel.
METHODS
Prospectively collected data on treatment-emergent AEs (frequency and grade [G]) from clinical trial databases of docetaxel
Temporal lobe tumor manifested by localized dysgeusia.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Undiagnosed lung cancer presenting with dysgeusia.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Drug-related Dysgeusia: A Systematic Review.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Integrin receptor imaging of breast cancer: a proof-of-concept study to evaluate 99mTc-NC100692.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
The present study was a proof-of-concept study to provide an initial indication of the efficacy and safety of imaging malignant breast tumors using (99m)Tc-NC100692. The agent is a small peptide with high affinity for integrin receptors that are upregulated and expressed preferentially on
Management of Adverse Events During Rucaparib Treatment for Relapsed Ovarian Cancer: A Review of Published Studies and Practical Guidance
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
The poly(ADP-ribose) polymerase inhibitor rucaparib is approved as monotherapy in the treatment and maintenance settings for women with relapsed ovarian cancer in the European Union and the United States. We review the safety profile of rucaparib in both settings and provide recommendations for the
Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus
- Töötab 55 keeles
- Taimsed ravimid, mida toetab teadus
- Maitsetaimede äratundmine pildi järgi
- Interaktiivne GPS-kaart - märgistage ürdid asukohas (varsti)
- Lugege oma otsinguga seotud teaduspublikatsioone
- Otsige ravimtaimi nende mõju järgi
- Korraldage oma huvisid ja hoidke end kursis uudisteuuringute, kliiniliste uuringute ja patentidega
Sisestage sümptom või haigus ja lugege ravimtaimede kohta, mis võivad aidata, tippige ürdi ja vaadake haigusi ja sümptomeid, mille vastu seda kasutatakse.
* Kogu teave põhineb avaldatud teaduslikel uuringutel
